Views: 43 Author: Unibest Industrial Publish Time: 2025-04-29 Origin: Site
Query Drug:Osilodrostat
Query Time:2025-04-29 09:47:02
*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Osilodrostat is used in adults to treat Cushing's disease that cannot be treated with pituitary surgery.
Cushing Syndrome
Source MEDRT
Source: MEDRT
Source MEDRT
Source MEDRT
Source DAILYMED
Source FDASPL
Source DAILYMED
Source FDASPL
Source DAILYMED
Source FDASPL
Source DAILYMED
Source FDASPL
Source DAILYMED
Source FDASPL
Source DAILYMED
Source FDASPL
Source FDASPL
Source DAILYMED
Cushing Syndrome
Source MEDRT
Source: MEDRT
Source MEDRT
Source MEDRT
[Last update] 2024-12-25
Osilodrostat's Innovator is RECORDATI RARE DISEASES INC
The unique dosage forms from the innovator include:1. TABLET;ORAL.
Index | Route | Brand Name | Labeler | Approval Date | Dosage |
---|---|---|---|---|---|
1 | TABLET;ORAL | ISTURISA | RECORDATI RARE DISEASES INC | Mar 6, 2020 | EQ 10MG BASE |
2 | TABLET;ORAL | ISTURISA | RECORDATI RARE DISEASES INC | Mar 6, 2020 | EQ 1MG BASE |
3 | TABLET;ORAL | ISTURISA | RECORDATI RARE DISEASES INC | Mar 6, 2020 | EQ 5MG BASE |
This drug still has 6 effective patents.
Patent Number | Submission Date | Expiration Date | Drug Substance Patent? | Drug Product Patent? |
---|---|---|---|---|
8609862 | Apr 3, 2020 | Jan 13, 2031 | ||
10143680 | Apr 3, 2020 | Jul 6, 2035 | Y | |
8835646 | Apr 3, 2020 | Aug 23, 2026 | Y | Y |
8314097 | Apr 3, 2020 | Mar 27, 2029 | Y | Y |
9434754 | Apr 3, 2020 | Jan 13, 2031 | Y | |
10709691 | Aug 6, 2020 | Oct 12, 2035 |
The innovator RECORDATI RARE DISEASES INC's portolio contains products with the following 12 API(s): CYSTEAMINE HYDROCHLORIDE, ETHOTOIN, IBUPROFEN LYSINE, PASIREOTIDE DIASPARTATE, MECHLORETHAMINE HYDROCHLORIDE, CARGLUMIC ACID, DACTINOMYCIN, BETAINE, INDOMETHACIN SODIUM, SUCCIMER, PASIREOTIDE PAMOATE, OSILODROSTAT PHOSPHATE
The above products are related to 48 diseases: Cystinosis, Epilepsy, Complex Partial, Seizures, Epilepsy, Tonic-Clonic, Spondylitis, Ankylosing, Arthritis, Rheumatoid, Inflammation, Gout, Arthritis, Juvenile, Menorrhagia, Fever, Osteoarthritis, Pain, Pain, Postoperative, Dysmenorrhea, Premenstrual Syndrome, Bursitis, Cushing Syndrome, Pleural Effusion, Malignant, Neoplasm Metastasis, Hodgkin Disease, Mycosis Fungoides, Hyperammonemia, Melanoma, Testicular Neoplasms, Choriocarcinoma, Sarcoma, Kaposi, Sarcoma, Ewing, Rhabdomyosarcoma, Neuroblastoma, Wilms Tumor, Soft Tissue Neoplasms, Uterine Neoplasms, Gestational Trophoblastic Disease, Retinoblastoma, Homocystinuria, Spondylitis, Ankylosing, Arthritis, Gouty, Arthritis, Rheumatoid, Inflammation, Ductus Arteriosus, Patent, Osteoarthritis, Pain, Tendinopathy, Bursitis, Lead Poisoning, Nervous System, Childhood, Cushing Syndrome, Cushing Syndrome